 "Moderna's vaccine may prevent some asymptomatic infections after first shot")
Moderna Inc said data from the late stage trial of its Covid-19 vaccine suggests that it could prevent some asymptomatic infections as soon as the first dose of the shot is given.
The vaccine maker said in briefing documents it submitted to the US Food and Drug Administration released on Tuesday that it had not yet completed its full analysis on the efficacy against asymptomatic infection.
Still, it said that 38 trial participants in the placebo arm of its trial tested positive for Covid-19 without exhibiting symptoms at the time of their second dose. That was nearly triple the number in the vaccine arm of the trial, where there were 14 positive tests from asymptomatic people.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%